Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria; ? Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AA

Press/Media

Period12 Apr 2019

Media coverage

1

Media coverage

  • TitleAlnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria; ? Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AA
    Media name/outletBusiness Wire
    Country/TerritoryUnited States
    Date12/04/19
    PersonsManisha Balwani
View all 1
View less